27.04.2011 • NewsJohnson & JohnsonSynthesportfolio

J&J To Buy Synthes For $21.5 Billion

U.S. healthcare conglomerate Johnson & Johnson is expected to announce a $21.5 billion deal to buy Swiss medical device maker Synthes on Wednesday, the Wall Street Journal said, citing people familiar with the matter.

The deal is expected to value Synthes at 159 swiss francs ($180.51) a share, the Journal said, citing one person familiar with the matter.

Shares of Synthes closed at 146.50 Swiss francs on Tuesday.

Last week, Synthes confirmed it was in merger talks with J&J about a deal that would be J&J's largest-ever acquisition and reshape the medical devices industry.

The Journal said J&J is expected to pay one-third cash and the remainder in stock as part of the deal.

Synthes declined to comment on the Journal report to Reuters. J&J could not immediately be reached for comment.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.